Clinical trial
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic…
NCT00281502 · Weill Medical College of Cornell University, Other · Unknown status
Key facts
| NCT number | NCT00281502 |
|---|---|
| Title | The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy |
| Official title | The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Collaborators | Bausch Health Americas, Inc. Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis |
| Intervention type | Drug |
| Interventions | Rifaximin (drug) |
| Enrollment | 50 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Jan 24, 2006 |
| Last update posted | Nov 5, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: